Search results for "29.0"

showing 10 items of 109 documents

Vegetation structure and greenness in Central Africa from Modis multi-temporal data.

2013

African forests within the Congo Basin are generally mapped at regional scale as broad-leaved evergreen forests, with a main distinction between terra-firme and swamp forests types. At the same time, commercial forest inventories, as well as national maps, have highlighted a strong spatial heterogeneity of forest types. A detailed vegetation map generated using consistent methods is needed to inform decision makers about spatial forest organisation and theirs relationships with environmental drivers in the context of global change. We propose a multi-temporal remotely sensed data approach to characterize vegetation types using vegetation index annual profiles. The classifications identified…

0106 biological scienceshttp://aims.fao.org/aos/agrovoc/c_28568Time Factors010504 meteorology & atmospheric sciencesDatabases FactualRainEcological Parameter Monitoringhttp://aims.fao.org/aos/agrovoc/c_900018001 natural sciencesTrees[ SDE ] Environmental Sciencesremote sensinghttp://aims.fao.org/aos/agrovoc/c_3062K01 - Foresterie - Considérations généralesDynamique des populationsForêt tropicale humidehttp://aims.fao.org/aos/agrovoc/c_6498http://aims.fao.org/aos/agrovoc/c_29008geography.geographical_feature_categoryCentral AfricaEcologyInventaire forestierVegetationArticlesClassificationSpatial heterogeneity[ SDE.MCG ] Environmental Sciences/Global ChangesDeciduoushttp://aims.fao.org/aos/agrovoc/c_7976CongoP31 - Levés et cartographie des solsForêt[SDE]Environmental SciencesSeasonshttp://aims.fao.org/aos/agrovoc/c_1432General Agricultural and Biological Scienceshttp://aims.fao.org/aos/agrovoc/c_34911Research ArticleF40 - Écologie végétaleTélédétectionClimate Change[SDE.MCG]Environmental Sciences/Global ChangesSpectroscopie infrarougeContext (language use)69Typologie010603 evolutionary biologySwampGeneral Biochemistry Genetics and Molecular BiologyCarbon Cycle[ SDU.ENVI ] Sciences of the Universe [physics]/Continental interfaces environmentHumansAfrica Centralhttp://aims.fao.org/aos/agrovoc/c_1666http://aims.fao.org/aos/agrovoc/c_1344http://aims.fao.org/aos/agrovoc/c_8176[SDU.ENVI]Sciences of the Universe [physics]/Continental interfaces environmenthttp://aims.fao.org/aos/agrovoc/c_6111Ecosystem0105 earth and related environmental sciencesChangement climatiquegeographyCartographiehttp://aims.fao.org/aos/agrovoc/c_24174Enhanced vegetation index15. Life on landEvergreenVégétationStructure du peuplement13. Climate actionCouvert forestierPhysical geographyU30 - Méthodes de recherchehttp://aims.fao.org/aos/agrovoc/c_1653tropical rainforestTropical rainforest
researchProduct

Análisis de los factores ligados al diagnóstico del trastorno por déficit de atención e hiperactividad en la infancia

2017

Resumen: Introducción: El trastorno por déficit de atención e hiperactividad (TDAH) es un trastorno neuropsiquiátrico de origen multifactorial. El objetivo de este estudio es determinar el porcentaje de pacientes que presentan TDAH del global de los enviados a la consulta por este motivo, y explorar los factores epidemiológicos y clínicos asociados al diagnóstico. Pacientes y métodos: Estudio retrospectivo analítico de una muestra de pacientes derivados a la consulta de neuropediatría por sospecha de TDAH, a la que se le aplican los criterios diagnósticos del DSM-IV. Se realiza un análisis de regresión logística para explorar los factores asociados al diagnóstico. Resultados: De los 280 pac…

03 medical and health sciences0302 clinical medicine030225 pediatricsClinical NeurologyNeurology (clinical)lcsh:Neurology. Diseases of the nervous systemlcsh:RC346-429030227 psychiatryNeurología
researchProduct

Consenso para el diagnóstico, tratamiento y seguimiento del paciente con distrofia muscular de Duchenne

2019

Resumen: Introducción: La distrofia muscular de Duchenne (DMD) es la miopatía más frecuente en niños, con una prevalencia mundial de aproximadamente 0,5 por cada 10.000 varones. Se caracteriza por una debilidad muscular progresiva al inicio de la infancia con aparición posterior de complicaciones musculoesqueléticas, respiratorias y cardíacas que ocasionan discapacidad, dependencia y muerte prematura. Actualmente su tratamiento se fundamenta en medidas sintomáticas multidisciplinares que han modificado favorablemente el curso de la enfermedad, por lo que resulta crucial establecer unas directrices claras y actualizadas que permitan tanto una detección temprana de la enfermedad como un adecu…

03 medical and health sciences0302 clinical medicineNeurology (clinical)lcsh:Neurology. Diseases of the nervous systemlcsh:RC346-429030217 neurology & neurosurgeryNeurología
researchProduct

Vascular pathology: Cause or effect in Alzheimer disease?

2018

Introduction: Alzheimer disease (AD) is the main cortical neurodegenerative disease. The incidence of this disease increases with age, causing significant medical, social and economic problems, especially in countries with ageing populations. Objective: This review aims to highlight existing evidence of how vascular dysfunction may contribute to cognitive impairment in AD, as well as the therapeutic possibilities that might arise from this evidence. Development: The vascular hypothesis emerged as an alternative to the amyloid cascade hypothesis as an explanation for the pathophysiology of AD. This hypothesis locates blood vessels as the origin for a variety of pathogenic pathways that lead …

0301 basic medicineContext (language use)DiseaseBlood–brain barrierlcsh:RC346-42903 medical and health sciences0302 clinical medicineAlzheimer DiseaseMaterials ChemistrymedicineDementiaHumanslcsh:Neurology. Diseases of the nervous systemNeuronsAmyloid beta-PeptidesVascular diseaseNeurodegenerationBrainmedicine.disease030104 developmental biologymedicine.anatomical_structureAgeingBlood-Brain BarrierCerebrovascular CirculationAlzheimer's diseasePsychologyNeuroscience030217 neurology & neurosurgeryNeurología (English Edition)
researchProduct

Modeling of Myotonic Dystrophy Cardiac Phenotypes in Drosophila

2018

After respiratory distress, cardiac dysfunction is the second most common cause of fatality associated with the myotonic dystrophy (DM) disease. Despite the prevalance of heart failure in DM, physiopathological studies on heart symptoms have been relatively scarce because few murine models faithfully reproduce the cardiac disease. Consequently, only a small number of candidate compounds have been evaluated in this specific phenotype. To help cover this gap Drosophila combines the amenability of its invertebrate genetics with the possibility of quickly acquiring physiological parameters suitable for meaningful comparisons with vertebrate animal models and humans. Here we review available des…

0301 basic medicineDaunorubicinDiseaseBioinformaticsMyotonic dystrophyMuscleblindlcsh:RC346-42903 medical and health sciencesCTG expansionmedicineDrosophilalcsh:Neurology. Diseases of the nervous systemmyotonic dystrophybiologyRespiratory distresscardiac dysfunctionCCTG expansionRNADrosophila disease modelbiology.organism_classificationmedicine.diseasePhenotype030104 developmental biologyNeurologyHeart failureNeurology (clinical)medicine.drugFrontiers in Neurology
researchProduct

An Assay to Determine Mechanisms of Rapid Autoantibody-Induced Neurotransmitter Receptor Endocytosis and Vesicular Trafficking in Autoimmune Encephal…

2019

N-Methyl-D-aspartate (NMDA) receptors (NMDARs) are among the most important excitatory neurotransmitter receptors in the human brain. Autoantibodies to the human NMDAR cause the most frequent form of autoimmune encephalitis involving autoantibody-mediated receptor cross-linking and subsequent internalization of the antibody-receptor complex. This has been deemed to represent the predominant antibody effector mechanism depleting the NMDAR from the synaptic and extra-synaptic neuronal cell membrane. To assess in detail the molecular mechanisms of autoantibody-induced NMDAR endocytosis, vesicular trafficking, and exocytosis we transiently co-expressed rat GluN1-1a-EGFP and GluN2B-ECFP alone or…

0301 basic medicineEndosomeautoantibodiesmedia_common.quotation_subjectN-Methyl-D-aspartate receptorsEndocytosisExocytosislcsh:RC346-42903 medical and health sciences0302 clinical medicineNeurotransmitter receptorendocytosisInternalizationReceptorlcsh:Neurology. Diseases of the nervous systemmedia_commonOriginal ResearchChemistryAutoantibodyautoimmune encephalitisCell biology030104 developmental biologynervous systemNeurologyRabNeurology (clinical)exocytosisvesicular trafficking030217 neurology & neurosurgerycross-linkingFrontiers in neurology
researchProduct

Coexpresión de NG2/GFAP tras la diferenciación en células transfectadas con las mutaciones de GFAP y en células procedentes de gliomas indiferenciados

2020

Resumen: Introducción: La enfermedad de Alexander es una enfermedad rara causada por mutaciones en el gen que codifica la proteína glial ácida fibrilar (GFAP). En un estudio previo hemos observado que la diferenciación de neuroesferas transfectadas con estas mutaciones genera un tipo celular que comparte la expresión de GFAP y NG2. Objetivos: Determinar el efecto de las mutaciones en marcadores moleculares en comparación con células de glioma diferenciados que expresan simultáneamente GFAP y NG2. Métodos: Se utilizaron muestras de glioblastoma humana (GLM) y neuroesferas procedentes de rata transfectadas con mutaciones de GFAP para el análisis de la expresión tras diferenciación de GFAP y N…

0301 basic medicineGFAPmacromolecular substancesGliomalcsh:RC346-42903 medical and health sciences030104 developmental biology0302 clinical medicinenervous systemCaspase-3Alexander diseaseNG2Neurology (clinical)030217 neurology & neurosurgerylcsh:Neurology. Diseases of the nervous systemNeurología
researchProduct

TLR4 participates in the transmission of ethanol-induced neuroinflammation via astrocyte-derived extracellular vesicles

2019

Background Current evidence indicates that extracellular vesicles (EVs) participate in intercellular signaling, and in the regulation and amplification of neuroinflammation. We have previously shown that ethanol activates glial cells through Toll-like receptor 4 (TLR4) by triggering neuroinflammation. Here, we evaluate if ethanol and the TLR4 response change the release and inflammatory content of astrocyte-derived EVs, and whether these vesicles are capable of communicating with neurons by spreading neuroinflammation. Methods Cortical neurons and astrocytes in culture were used. EVs were isolated from the extracellular medium of the primary culture of the WT and TLR4-KO astrocytes treated …

0301 basic medicineImmunologyInflammationlcsh:RC346-42903 medical and health sciencesCellular and Molecular NeuroscienceMice0302 clinical medicineWestern blotNeuroinflammationGlial cellsExtracellularmedicineAnimalsProtein Interaction MapsReceptorNeuroinflammationCells Culturedlcsh:Neurology. Diseases of the nervous systemInflammationMice KnockoutNeuronsmedicine.diagnostic_testEthanolChemistryGeneral NeuroscienceResearchExtracellular vesiclesCell biologyMice Inbred C57BLToll-Like Receptor 4030104 developmental biologymedicine.anatomical_structureNeurologyAstrocytesTLR4medicine.symptom030217 neurology & neurosurgeryIntracellularAstrocyteJournal of Neuroinflammation
researchProduct

Deep Brain Stimulation and L-DOPA Therapy: Concepts of Action and Clinical Applications in Parkinson's Disease.

2018

L-DOPA is still the most effective pharmacological therapy for the treatment of motor symptoms in Parkinson's disease (PD) almost four decades after it was first used. Deep brain stimulation (DBS) is a safe and highly effective treatment option in patients with PD. Even though a clear understanding of the mechanisms of both treatment methods is yet to be obtained, the combination of both treatments is the most effective standard evidenced-based therapy to date. Recent studies have demonstrated that DBS is a therapy option even in the early course of the disease, when first complications arise despite a rigorous adjustment of the pharmacological treatment. The unique feature of this therapeu…

0301 basic medicineLevodopaParkinson's diseaseDeep brain stimulationglobus pallidus internus (GPi)medicine.medical_treatmentParkinson's diseaseCentral nervous systemStimulationDiseaseReviewlcsh:RC346-42903 medical and health sciencesTherapeutic approach0302 clinical medicinemedicinelevodopadeep brain stimulation (DBS)lcsh:Neurology. Diseases of the nervous systembusiness.industryDopaminergicmedicine.diseasenervous system diseases030104 developmental biologymedicine.anatomical_structureNeurologyNeurology (clinical)businessNeurosciencesubthalamic nucleus (STN)030217 neurology & neurosurgerymedicine.drugFrontiers in neurology
researchProduct

PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disorders

2020

Since their introduction in 1999, anti-tumour necrosis factor-α (anti-TNF-α) therapies have been suspected repeatedly to be associated with the occurrence of central nervous system (CNS) demyelinating disorders, including multiple sclerosis (MS). However, recent publications were restricted to descriptions of monophasic demyelinating events or cases of relapsing–remitting MS (RRMS). We here provide the first case report of primary progressive MS (PPMS) onset upon anti-TNF-α therapy as well as a literature review of previously published cases of anti-TNF-α therapy-associated MS onset. The 51-year old male patient was treated with adalimumab due to psoriasis arthritis. About 18 months after …

0301 basic medicineNecrosisCentral nervous systemprimary progressive multiple sclerosisPrimary Progressive Multiple SclerosisCase ReportAnti-TNF-alpha therapylcsh:RC346-42903 medical and health sciences0302 clinical medicineadalimumabmedicineAdalimumabanti-TNF-alpha therapyDemyelinating DisorderAnti tnf α therapylcsh:Neurology. Diseases of the nervous systemPharmacologybusiness.industry030104 developmental biologymedicine.anatomical_structureNeurologyImmunologyNeurology (clinical)medicine.symptombusiness030217 neurology & neurosurgerymedicine.drugTherapeutic Advances in Neurological Disorders
researchProduct